Schroder Investment Management Group
MLYS icon

Schroder Investment Management Group’s Mineralys Therapeutics MLYS Stock Holding History

Schroder Investment Management Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.26M Buy
307,214
+176,622
+135% +$4.85M 0.01% 705
2026
Q1 		$3.07M Hold
130,592
– – ﹤0.01% 856
2025
Q4 		$4.64M Buy
+130,592
New +$5.24M ﹤0.01% 758
2025
Q2 		– Sell
-62,893
Closed -$922K – 1219
2025
Q1 		$922K Buy
+62,893
New +$723K ﹤0.01% 1004

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Schroder Investment Management Group's MLYS Position: Q2 2026 in Review

Schroder Investment Management Group increased its Mineralys Therapeutics (MLYS) stake by 135% in Q2 2026, buying an estimated $4.85M and bringing the position to 307,214 shares worth $8.26M. The position accounts for 0.01% of the portfolio, ranked #705.

Schroder Investment Management Group first reported a position in MLYS in Q1 2025 and has held it in 4 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Schroder Investment Management Group held 307,214 shares of Mineralys Therapeutics worth $8.26M as of Q2 2026.
  • Schroder Investment Management Group bought 176,622 Mineralys Therapeutics shares in Q2 2026, an estimated $4.85M.
  • Mineralys Therapeutics made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #705 holding.
  • Schroder Investment Management Group first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.